Bayer Aktiengesellschaft (BAYRY)

OTCMKTS · Delayed Price · Currency is USD
7.80
+0.25 (3.31%)
Jul 1, 2025, 3:59 PM EDT
10.80%
Market Cap 30.60B
Revenue (ttm) 50.34B
Net Income (ttm) -3.52B
Shares Out n/a
EPS (ttm) -3.59
PE Ratio n/a
Forward PE 5.74
Dividend 0.02 (0.29%)
Ex-Dividend Date Apr 29, 2025
Volume 97,961
Average Volume 571,668
Open 7.68
Previous Close 7.55
Day's Range 7.68 - 7.81
52-Week Range 4.79 - 8.58
Beta 0.98
RSI 59.36
Earnings Date Aug 6, 2025

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]

Sector Healthcare
Founded 1863
Employees 91,864
Stock Exchange OTCMKTS
Ticker Symbol BAYRY
Full Company Profile

Financial Performance

In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.

Financial numbers in EUR Financial Statements

News

Bayer Appoints Priyal Patel as Chief Financial Officer for North America

ST. LOUIS--(BUSINESS WIRE)--Bayer today announced the appointment of Priyal Patel as Cluster Chief Financial Officer (CFO) for North America, effective July 1, 2025. In her new role, Patel will overse...

16 hours ago - Business Wire

US Supreme Court seeks Justice Department views on Bayer's Roundup appeal

The U.S. Supreme Court asked President Donald Trump's administration on Monday for its views on Bayer's bid to sharply limit lawsuits claiming that the company's Roundup weedkiller causes cancer and p...

1 day ago - Reuters

Bayer says U.S. Supreme Court asks solicitor general for opinion in glyphosate case

Bayer said on Monday that the U.S. Supreme Court had asked the solicitor general for an opinion in the Durnell case, as the German company seeks clarity from the top U.S. court in litigation related t...

1 day ago - Reuters

Court Approves $38M Cash Settlement Against Bayer AG in Hard-Fought Securities Class Action

Following the Bayer-Monsanto merger, litigation has resulted in a valuable settlement that, pending final approval, affirms the rights of ADR investors to

4 days ago - GlobeNewsWire

Bayer, Regeneron get EU nod for Eylea's label extension

Bayer's Eylea 8 mg gets EU approval for extended 6-month dosing for macular degeneration & diabetic macular edema. Read more here.

4 days ago - Seeking Alpha

Bayer share price is rising: does it have more upside?

Bayer share price has bounced back this year, making it one of the best-performing companies in the German DAX Index. It has jumped to €26, up by 45% from its lowest point this year.

5 days ago - Invezz

EY US & Bayer Win “Artificial Intelligence for Good” Award in 2025 AI Breakthrough Awards Program

Prestigious International Annual Awards Program Honors Standout AI Companies & Solutions Prestigious International Annual Awards Program Honors Standout AI Companies & Solutions

6 days ago - GlobeNewsWire

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars

On Sunday, Exelixis, Inc. (NASDAQ: EXEL) revealed topline results from the STELLAR-303 phase 3 pivotal trial of zanzalintinib (100 mg) combined with atezolizumab . The study includes patients with pr...

8 days ago - Benzinga

Bayer’s stock is charting a 40% rebound after years of losses

Bayer surged almost 40% in 2025, ranking among the DAX’s top performers. The rally has pushed its share price close to surpassing the average 12-month analyst target.

13 days ago - Fortune

Bayer Files for Approval of gadoquatrane in the U.S.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational contrast agent gadoquatrane f...

14 days ago - Business Wire

Captain T Cell Joins Bayer Co.Lab Berlin to Accelerate Autologous and Allogeneic TCR-T Cell Therapy Programs for Cancer Patients

Berlin, Germany – June 17th, 2025 – Captain T Cell GmbH, a biotech company developing next-generation TCR-based cell therapies for patients with solid tumors, today announced that it has been selected...

14 days ago - GlobeNewsWire

Bayer Innovation Procurement Expands Use of Scientist.com's AI-Powered Platform for Global R&D Procurement Orchestration

SAN DIEGO--(BUSINESS WIRE)-- #innovation--Bayer AG Innovation Procurement names Scientist.com as preferred global channel for sourcing external R&D services.

15 days ago - Business Wire

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

BERLIN & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bayer and the Broad Institute today announced that they have extended their research collaboration of 10 years by an additional five years, to further advan...

20 days ago - Business Wire

Bayer Crop Science delegation visits ISARC

Bayer Crop Science delegation visits ISARC : A four-member delegation from Bayer Crop Science visited the International Rice Research Institute - Sout.

27 days ago - The Times of India

Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor

SAN DIEGO & BERLIN, Germany--(BUSINESS WIRE)--Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, ...

27 days ago - Business Wire

Bayer to Share New Data from KERENDIA® (finerenone) Clinical Trial Program at European Renal Association Congress

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that it will present multiple new analyses of the KERENDIA ® (finerenone) clinical trial program at the European Renal Association (ERA) 62nd Con...

4 weeks ago - Business Wire

Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals

German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge over Roche'...

5 weeks ago - Reuters

Bayer Launches Centafore Imaging Core Lab to Support Imaging for Clinical Trials and Software as a Medical Device Development

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the launch of its Imaging Core Lab Services under the brand name Centafore. With over 25 years of experience supporting more than 200 clinical tr...

5 weeks ago - Business Wire